Document:

<PAGE>
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                                                   EXHIBIT 10.19

                                    GTX INC.
                                      [ * ]

                                INQUIRY NO. [ * ]

                                 AUGUST 8, 2003
<PAGE>
                                   EAGLEPICHER

                             PHARMACEUTICAL SERVICES

                           CONFIDENTIAL AND RESTRICTED

This contract contains confidential and proprietary information of GTx, Inc. The
contents of this contract will be restricted to those EPPS personal with a need
to know the contents hereof.
<PAGE>
                                TABLE OF CONTENTS

                                   (CONTINUED)

<TABLE>
<CAPTION>
                                                                     PAGE
<S>                                                                  <C>
I.     Introduction.................................................   4

II.    Proposed Services............................................   4

III.   Deliverables................................................   10

IV.    Project Budget..............................................   10

V.     Timelines...................................................   10

VI.    Assumptions.................................................   10

VII.   Designated Representatives..................................   12

VIII.  Standard Terms and Conditions...............................   12

IX.    Insurance...................................................   12

X.     Project Authorization.......................................   13
</TABLE>
<PAGE>
I.    INTRODUCTION

      GTx Inc. has requested a quotation for [ * ] prepared under current good
      manufacturing practices (cGMP). Eagle Picher Pharmaceutical Services
      (EPPS) has extensive experience with [ * ] and we are excited to utilize
      this knowledge to assist GTx in the development and manufacturing of [ *
      ]. Our customer focus and commitment to delivering the right product at
      the right time and at the right price is unmatched by our competition.

II.   PROPOSED SERVICES

      SCOPE OF WORK SUMMARY

      EPPS will manufacture [ * ] of [ * ] in our API plant equipment. This will
      involve scaling up the current manufacturing process [ * ] into our plant
      equipment ([ * ]). EPPS will make every effort to manufacture [ * ] with
      the same target purity as previous kilo lab campaigns.

      A [ * ] process is used to manufacture [ * ]. The [ * ] are outlined in
      the `Detailed Scope of Work' section of this proposal. To limit the risk
      as larger production batches are manufactured and to continue the
      development of the process EPPS will execute the following activities:

      Phase I- Analytical Method Transfer & Validation
             -Demonstrate and incorporate assay methods for [ * ].
             -Validate and incorporate [ * ].
             -Transfer [ * ] assay methods from [ * ] to be used to assay the
             [ * ] and [ * ].
             -Perform analytical method validations for key intermediate [ * ].
             -Perform abbreviated analytical method validations for each of the
             [ * ] intermediates.
             -Incorporate in-process monitoring assays for [ * ].
             -Characterize a working standard for the [ * ].
             -Set specifications for the release of the [ * ]. A lab batch will
             be performed to generate [ * ]. Specifications will be proposed
             based upon the analysis of these [ * ] of the [ * ].
             -Validate analytical methods for release testing of [ * ] ([ * ]).

      Phase II- GMP Set-up Activities for Pilot Plant Production of [ * ]
             [ * ] batch records for plant equipment and processing.
             [ * ] validation studies to develop [ * ] plant equipment.
             -Project process training for [ * ].

      Phase III- cGMP production of [ * ]
             -[ * ] (assuming no [ * ] are removed)
             -Certificate of Analysis for cGMP Batch

                                       4
<PAGE>
            -Production Report

      DETAILED SCOPE OF WORK

      EPPS will manufacture [ * ] of [ * ] in our API Plant equipment. The
      manufacture of [ * ] is a [ * ] process and is outlined below. Prior to
      manufacture of each step in the plant equipment the analytical method
      transfer/validation and GMP set-up activities for that step will be
      completed. All EPPS analytical support for this project will be conducted
      at the [ * ] facility.

      [ * ]

      PHASE I- ANALYTICAL METHOD TRANSFER & VALIDATION

      [ * ]
      EPPS will validate the [ * ] from [ * ]. A validation protocol will be
      submitted to GTx for approval prior to execution. The validation protocol
      will follow the [ * ], and the method will be validated for the following:

            o Specificity ([ * ]),
            o Accuracy,
            o Precision,
            o Linearity,
            o Quantitation Limit,
            o Detection Limit,
            o Robustness, and
            o Range.

      The validated procedure will be converted into EPPS's [ * ]. NOTE: A
      specification for [ * ] that includes an acceptable level of [ * ] will be
      defined before the validation protocol can be approved. The analytical
      method validation report will be provided to GTx as a deliverable. The
      [ * ] method will meet the validation parameters or GTx will be notified.

      An assay method for [ * ] will be obtained from the vendor and used for
      the release testing. An STM will be written for use in the release testing
      of this raw material. The current standard test specifications (STS) for
      [ * ] will be updated to add this assay to the current specifications.
      Vendor specifications will be used for the STS.

      An [ * ] test will be used to monitor the completion of the reaction in
      [ * ]. The proposed test will use the assay method supplied by [ * ]. The
      method will work to measure the [ * ] or GTx will be notified.

      The [ * ] will be tested for release using the [ * ] assay method. A
      working standard of [ * ] will be characterized. The working standard of
      [ * ] (approximately [ * ]) will be characterized by [ * ]. The method to
      measure the assay [ * ] will have an abbreviated

                                       5
<PAGE>
      validation performed using the following tests on one sample: Accuracy,
      Precision, Linearity, Quantitation Unit, and Stability [ * ]. The method
      will not be validated at this time. The method will be shown to be
      validatable by performing these tests on [ * ]. The method will perform
      adequately on the [ * ] or GTx will be notified. A report will be written
      summarizing the results.

      Samples of [ * ] from previous work at EPPS will be tested by [ * ] to
      determine an [ * ] profile. The information obtained from this analysis
      will be used to establish release specifications for [ * ]. The standard
      test specification (STS) for [ * ] will be modified accordingly.

      [ * ]
      [ * ] will be tested using the manufacturer's method for assay. A Standard
      Test Method will be written for this raw material. The current STS for
      [ * ] will be updated to add an assay to the current specifications.
      Vendor specifications will be used for the STS.

      The [ * ] is not isolated in the current process. However, the reaction to
      form [ * ] should be monitored for completion using an [ * ] test. EPPS
      will use [ * ] assay method for the in-process monitoring of [ * ]. The
      method will work to measure the disappearance of starting materials and/or
      appearance of the product in the reaction or GTx will be notified.

      A working standard of [ * ] ([ * ]) will be characterized. The working
      standard will be characterized by [ * ]. The assay method for [ * ] will
      have an abbreviated validation performed using the following tests on one
      sample: Accuracy, Precision, Linearity, Quantitation Limit and Stability
      [ * ]. The method will not be validated at this time. The method will be
      shown to be validatable by performing these tests on one sample of
      intermediate. The method will perform adequately on the intermediate or
      GTx will be notified. A report will be written summarizing the results.

      Samples of [ * ] from previous work at EPPS will be used to determine an
      impurity profile for this intermediate. This profile will be used to
      establish the standard test specifications (STS) for [ * ]. The STS will
      be modified to include an assay.

      [ * ] is combined with [ * ] in the manufacturing process. The [ * ]
      method for [ * ] will be validated. A validation protocol will be
      submitted to GTx for approval prior to execution. The validation protocol
      will follow the [ * ], and the method will be validated for the following:

            o Specificity,
            o Accuracy,
            o Precision,
            o Linearity,
            o Quantitation Limit,
            o Detection Limit,

                                       6
<PAGE>
            o Robustness, and
            o Range.

      The assay method will perform adequately or GTx will be notified. A
      validation report will be issued for this work.

      A working standard of [ * ] will be prepared. The material will be
      characterized by [ * ]. Because [ * ] may be stored for longer periods of
      time, some stress studies will be performed to assess how labile the
      compound is under certain conditions. Forced degradation studies will
      examine [ * ].

      Samples of [ * ] from previous work at EPPS will be used to determine the
      impurity profile of this material. This profile will be used in
      establishing the standard test specifications (STS) for [ * ]. The STS
      will be modified to include an assay in the specification.

      [ * ]

      [ * ] will be tested for release using the manufacturer's method for
      assay. A STM will be written for this raw material. The current STS for
      [ * ] will be updated to add an assay to the current release tests. Vendor
      specifications will be used for the STS.

      An assay method for [ * ] will be obtained from the vendor and used for
      the release testing. A STM will be written to use for this raw material.
      The current STS for [ * ] will be updated to add an assay to the current
      specifications. Vendor specifications will be used for the STS.

      In-process monitoring of [ * ] will use the assay method supplied by
      [ * ]. The method will work to measure the [ * ] or GTx will be notified.

      The [ * ] will be tested for release using the [ * ] assay method. The
      scope for this [ * ] is similar to the scope of work proposed for [ * ]. A
      working standard of [ * ] will be characterized, The working standard
      ([ * ]) will be characterized by [ * ]. The [ * ] assay method for [ * ]
      will have an abbreviated validation performed using the following tests on
      one sample: Accuracy, Precision, Linearity, Quantitation Limit, and
      Stability per [ * ]. The method will not be validated at this time. The
      method will be shown to be validatable by performing these tests on one
      sample of [ * ]. The method will perform adequately on the [ * ] or GTx
      will be notified. A report will be written summarizing the results.

      Samples of [ * ] from previous work at EPPS will be used to determine an
      [ * ]. This profile will be used in the determination of the standard
      specifications of [ * ]. The STS sheet will be modified to include a [ * ]
      assay.

      [ * ]

                                       7
<PAGE>
      The [ * ] will be tested using the manufacturer's method for assay. A STM
      will be written for the assay of this raw material. The current STS for
      [ * ] will be updated to add an assay to the current tests. Vendor
      specifications will be used for the STS.

      Similarly, the [ * ] will be tested using the manufacturer's method for
      assay. A STM will be written for the assay of this raw material. The
      current STS for [ * ] will be updated to add an assay to the current
      tests. Vendor specifications will be used for the STS.

      In-process [ * ] monitoring of the [ * ] reaction will use the assay
      method supplied by [ * ]. The method will work to measure the [ * ] or GTx
      will be notified.

      The [ * ] methods ([ * ]) for release testing of [ * ] will be transferred
      to EPPS and validated on [ * ]. EPPS will write a validation protocol
      which will be approved by GTx prior to validation. Using [ * ], the method
      will be validated for the following; Specificity ([ * ]), Accuracy,
      Precision, Linearity, Quantitation Limit, Detection Limit, Robustness, and
      Range. Each method will be incorporated into a STM for GMP analysis. A
      validation report will be written. The methods will work properly or GTx
      will be notified.

      The [ * ] method for [ * ] testing of [ * ] ([ * ]) will be transferred to
      EPPS and validated for [ * ]. The [ * ] methods for [ * ] will be
      validated. A validation protocol will be submitted to GTx for approval
      prior to execution. The validation protocol will follow the [ * ], and the
      method will be validated for the following:

            o Specificity ([ * ]),
            o Accuracy,
            o Precision,
            o Linearity,
            o Quantitation Limit,
            o Detection Limit,
            o Robustness, and
            o Range.

      If portions of the validation program proposed above have been performed
      at [ * ] then that work will not be repeated. A validation report will be
      written. The methods will work properly or GTx will be notified.

      Product specific methods for [ * ] will be validated by EPPS. EPPS will
      write a validation protocols and will submit these protocols to GTx for
      approval prior to implementation. Using the [ * ], the method will be
      validated for the following; Specificity and Accuracy. Each method will be
      incorporated into a STM. A validation report will be written. The methods
      will work properly or GTx will be notified.

      PHASE II- GMP SET-UP ACTIVITIES FOR PILOT PLANT PRODUCTION OF [ * ]

                                       8
<PAGE>
      A series of [ * ] are required prior to the pilot plant campaign.

         o  [ * ] will be rewritten for pilot plant production. The [ * ] will
            be submitted to GTx for approval then issued by EPPS's QA
            department.

         o  EPPS and GTx will review [ * ] prior to starting plant
            manufacturing.

         o  [ * ] will be performed to develop procedures that will be used to
            1) [ * ] and 2) [ * ]. This usually entails [ * ] and [ * ] to
            document the [ * ] is sufficient.

         o  EPPS requires operator training and a safety review of the process
            before the start of manufacturing. The operators are trained on how
            to handle the chemicals used in the process and their hazards.

      PHASE III- CGMP PRODUCTION OF [ * ]

      A cGMP batch of [ * ] will be manufactured utilizing the best technology
      developed during previous [ * ]. [ * ] and [ * ] will be combined, as in
      the [ * ]. Each [ * ] will be released based on the specifications
      established in [ * ]. In-process reaction monitoring will be performed on
      [ * ].

      GTx will supply the [ * ] starting material. EPPS will provide all [ * ]
      including the [ * ] and [ * ].

      The [ * ] will include [ * ],

      After completion of the production campaign, a production report will be
      issued which will include a summary of the [ * ].

      The, QC department typically provides in-process results from production
      samples [ * ]. The analyses required to [ * ] typically has a [ * ] time.
      Final release testing usually takes about [ * ] for [ * ] and [ * ]. If
      any rush charges are incurred for rush analysis from outside vendors, the
      cost will be [ * ].

      The storage conditions for [ * ] and the [ * ] will be at [ * ] unless
      otherwise requested by GTx. The final product will be packaged in [ * ]
      inside of [ * ]. The label is in accordance with the [ * ]. The scope of
      this work has incorporated [ * ].

      GTx will always have the options to [ * ].

                                       9
<PAGE>
III.  DELIVERABLES

         o  Validation Report - [ * ]
         o  Summary Report - [ * ]
         o  Summary Report - [ * ]
         o  Validation Report for [ * ]
         o  Summary Report - [ * ]
         o  Validation Report for [ * ]
         o  Validation Report for [ * ]
         o  Validation Report - [ * ]
         o  [ * ] of [ * ] ([ * ])
         o  Certificate of Analysis for cGMP Batch
         o  Production Report

IV.   PROJECT BUDGET

<TABLE>
<CAPTION>
  PHASE        DESCRIPTION                                       COST
<S>            <C>                                               <C>
    I          Analytical Method Transfer and Validation         [ * ]
    II         GMP Set-up Activities                             [ * ]
   III         GMP Production ([ * ])                            [ * ]
               Raw Materials and Waste                           [ * ]
                      TOTAL                                      [ * ]
</TABLE>

V.    TIMELINES

      [ * ]

      o     Phase I - [ * ] from the date the proposal is signed. Phase I [ * ]
            with GMP production.
      o     Phase II - [ * ] from the date the proposal is signed.
      o     Phase III - [ * ] after completion of Phase II.

VI.   ASSUMPTIONS

      EPPS is providing this proposal with the following assumptions. Should any
      of these assumptions prove to be invalid; a revised scope of work with its
      associated cost will be submitted to GTx.

      1.    GTx will provide [ * ] at GTx expense. All remaining raw materials
            are included in this quote, including [ * ] and [ * ].

      2.    Any changes to this Agreement which effect cost, schedule, or alter
            this Agreement materially, such as changes in processes, protocols
            or additional testing or sampling,

                                       10
<PAGE>
            shall be submitted in writing with any additional associated costs
            and mutually agreed to by both parties before continuation of the
            project.

      3.    The API manufactured at EPPS is not manufactured as a sterile API.
            The customer will ensure that if a sterile product is required that
            the formulated product will contain steps for terminal
            sterilization.

      4.    This proposal does not include costs for an FDA site inspection as a
            result of or in association with the manufacturing of the API named
            in this proposal.

      5.    EPPS makes no guarantees on yield or purity until [ * ] EPPS
            manufacturing runs provide adequate information for justification of
            yield and purity consistency.

      6.    GTx bears all sales tax liability under this agreement. GTx is not
            liable for taxes on EPPS income.

      7.    Costs outlined above do not include any shipping outside of the
            scope provided in this proposal, shipping insurance, applicable
            taxes or handling charges.

      8.    [ * ] analytical methods will be suitable and provide acceptable
            performance (validatable) for use as described in the detailed scope
            of work.

                                       11
<PAGE>
VII.  DESIGNATED REPRESENTATIVES

         GTX, INC

         Karen Veverka, Ph.D.
         Director ARTA Research
         Three North Dunlap Avenue
         Van Vleet Building Third Floor
         Memphis, TN 38163
         901-523 -9700 ext 104
         fax 901-523-9772
         Kveverka@gtxinc.com

         EAGLEPICHER EAGLEPICHER PHARMACEUTICAL SERVICES

         Emily Russell
         Contracts Manager and Legal Administrator
         13605 W. 96th Terrace
         Lenexa, Kansas 66215
         800-233-6643
         913-888-3582
         Emily.russell@eaglepicher.com

VIII. STANDARD TERMS AND CONDITIONS

      The terms and conditions between GTx and EPPS for this contract are
      covered under the Production and Manufacturing Agreement entered into on
      the 9th day of September 2002, (the "2002 Agreement"). In the event of a
      conflict between the terms hereof and any provision contained in the 2002
      Agreement, the terms hereof shall control; otherwise, the 2002 Agreement
      shall be incorporated herein and form a put of this Agreement.

IX.   INSURANCE

      EPPS confirms that it has reasonable and adequate insurance in full force
      and effect with qualified insurers to fully insure GTx against loss of
      material or product resulting from a casualty occurring while such
      material or product is in control of or on the property of EPPS. EPPS will
      assume the risk of any loss to GTx material and property which is
      willingly under its control or located on its property, and in the event
      of a casualty, EPPS will promptly notify GTx. Pending resolution of any
      resulting insurance claim, EPPS will replace any lost or damaged material.

                                       12
<PAGE>
X.    PROJECT AUTHORIZATION

      The project described above may be authorized by returning to EaglePicher
      Pharmaceutical Services a signed copy of our proposal and your purchase
      order. This proposal remains effective until September 08, 2003. This
      proposal is subject to the attached Standard Terms and Conditions. Please
      reference EaglePicher Pharmaceutical Services Inquiry [ * ] in all
      correspondence. This agreement shall be interpreted and constructed in
      accordance with the laws of the state of Missouri. Termination of this
      agreement is subject to discussion and resolution of any outstanding
      issues between the involved parties.

<TABLE>
<S>                                         <C>
Sincerely,                                  Accepted by GTx, Inc:

/s/ Emily S. Russell                        /s/ Henry P. Doggrell  Date: 8/13/03
--------------------                        ---------------------        -------

Emily S. Russell                            General Counsel
Contracts Manager and Legal Administrator   Secretary
EaglePicher Technologies, LLC
</TABLE>

EaglePicher Pharmaceutical Services looks forward to your response, and to
proceeding as soon as possible.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       13<PAGE>
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                                                   EXHIBIT 10.20

              THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION AND

                                    GTX, INC.

                AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT

      Exclusive License Agreement (hereinafter "Agreement") made and entered
into this 23d day of August, 2000 (the "Effective Date") by and between The
University Of Tennessee Research Corporation, a corporation duly organized and
existing under the laws of the State of Tennessee and having its principal
office at 1534 White Avenue, Knoxville, Tennessee, U.S.A. (hereinafter "UTRC"),
and GTx, Inc. (formerly known as Genotherapeutics, Inc.) a Tennessee
corporation, located at 3 N. Dunlap St., 3rd Floor, Memphis, Tennessee 38163
(hereinafter "GTx").

      WHEREAS, UTRC is the owner of the Licensed Patents and Licensed Technology
(as later defined herein) the subject matter of which was developed by James T.
Dalton and Duane D.Miller, Leonid I. Kirkovsky, Arnab Mukherjee, Craig Marhefka,
and Donghua Yin ("Contributors") in the course of employment with The University
of Tennessee;

      WHEREAS, UTRC is willing to grant and GTx desires to receive an exclusive
worldwide license with rights to grant sublicenses and permit sub-sublicenses
under the Licensed Patents and Licensed Technology.

      NOW, THEREFORE, for and in consideration of the premises and other good
and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, UTRC and GTx (hereinafter referred to individually as a "Party"
and collectively as the "Parties") hereto expressly agree as follows:

                                   SECTION 1

                                   Definitions

      1.1 "Affiliates" shall mean any corporation, partnership, or other entity
that at any time during the term of this Agreement, directly or through one or
more intermediaries, Controls or is Controlled by or is under common Control
with a party to this Agreement, but only for so long as the relationship exists.
A corporation or other entity shall no longer be an Affiliate when through loss,
divestment, dilution or other reduction of ownership, the requisite Control no
longer exists.

      1.2 "Alliance" shall mean a relationship (including any entity formed as a
result thereof) entered into by GTx, with one or more third parties to
manufacture, use or sell a Licensed Product, Licensed Process or Licensed
Technology, which can include the

                                       1.
<PAGE>

development, manufacturing, distribution and/or marketing of a Licensed Product,
Licensed Process or Licensed Technology as a part of the relationship.

      1.3 "Control" or "Controls" or "Controlled" shall mean: i) in the case of
a corporation, ownership or control, directly or indirectly, of at least fifty
one percent (51%) of the shares of stock entitled to vote for the election of
directors; or ii) in the case of an entity other than a corporation, ownership
or control, directly or indirectly, of at least fifty one percent (51%) of the
assets of such entity.

      1.4 "Generic Product(s)" shall mean a commercial product the use, sale or
distribution of which utilizes Licensed Technology that is not covered in whole
or in part by a Valid Claim of the Licensed Patents. A product that is sold,
distributed or used for testing, development, or clinical trial purposes shall
not be considered a commercial product.

      1.5 "GTx" shall mean GTx and/or its Affiliates, unless otherwise clearly
indicated by the context.

      1.6 "Joint Alliance" shall mean an Alliance in which GTx either, (1)
receives a royalty of at least [ * ] percent [ * ] of net sales of Licensed
Product in any one or more of the Major Markets or (2) retains [ * ] percent
[ * ] or more of the net profits from the sale of Licensed Product in any one or
more of the Major Markets, determined in accordance with generally accepted
accounting principles.

      1.7 "Joint Alliance Party" or "Joint Alliance Parties" shall mean GTx and
any other party who is a member of a Joint Alliance, including Sub-sublicensees.

      1.8 "Joint Alliance Revenue" shall mean the amount received by a Joint
Alliance or a Joint Alliance Party from Third Parties for the use, sale or
distribution of a Licensed Product, Licensed Process or Generic Product, less:

         I) discounts allowed in amounts customary in the trade for quantity
purchases, cash payments, prompt payments, wholesalers and distributors;

         II) sales, tariff duties and/or use taxes directly imposed and with
reference to particular sales;

         III) outbound transportation prepaid or allowed, amounts allowed or
credited on returns, export licenses, import duties, value added tax, and
prepaid freight;

         IV) royalties, cash, fees, or other consideration paid to, or invoiced
by, Third Parties to a Joint Alliance or a Joint Alliance Party which are
considered payment of, or for technology and/or patent licensing fees for
manufacture, use, or sale of a Licensed Product, Licensed Process or Generic
Product; and

         V) sales commissions paid to individuals who are not employees of a
Joint Alliance or a Joint Alliance Party.

                                       2.
<PAGE>

No deductions shall be made for sales commissions paid to individuals who are
employees of a Joint Alliance or a Joint Alliance Party, or for cost of
collections.

      1.9 "Licensed Patents" shall mean the following:

            (1)   U.S. Patent No. [ * ], issued [ * ], entitled [ * ];

            (2)   U.S. Patent No. [ * ], issued [ * ], entitled [ * ];

            (3)   U.S. Patent No. [ * ], issued [ * ], entitled [ * ]; and

together with the list of patents pending and/or issued for the Licensed
Technology set forth on Schedule 1 attached hereto and made a part hereof, and
any other patent applications that may in the future be filed by GTX on the
Licensed Technology and any patents issuing therefrom, including any
application(s) filed by GTx pursuant to Articles 6.1 and 6.7 of this Agreement,
whether in the United States of America or any other country, including any and
all substitutions for and divisions, continuations, continuation-in-part,
provisionals, and non-provisionals, renewals, reissues, any foreign patent
applications and divisionals or national phase applications which claim priority
of any of Provisional Application Serial Number [ * ], filed [ * ]; Provisional
Application Serial Number [ * ], filed [ * ]; Provisional Application Serial
Number [ * ], filed [ * ].

      1.10 "Licensed Process(es)" shall mean any process which is covered in
whole or in part by a Valid Claim of the Licensed Patents.

      1.11 "Licensed Product(s)" shall mean any product that:

            I)    is covered in whole or in part by a Valid Claim of the
                  Licensed Patents; or

            II)   is manufactured by using a process or is employed to practice
                  a process which is covered in whole or in part by a Valid
                  Claim of the Licensed Patents.

      1.12 "Licensed Technology" shall mean any technology, trade secrets,
methods, processes, know-how, show-how, data, information, or results relating
to UTRC PD numbers [ * ] developed by the Contributors, and owned by UTRC,
including: 1) agents, compositions, compounds, or analogs or isomers thereof, of
nonsteroidal molecules which bind to androgen receptors, including radiolabeled,
fluorescent, and radioisotopes incorporated thereto and small molecules of
R-bicalutamide, androgen receptor targeting agents, oral testosterone
compositions; 2) methods of making developing, or characterizing such agents,
compositions, and composition, compounds of (1); and 3) any therapeutic,
diagnostic, and prognostic methods of use, of such compounds or agents of (1)
including but not limited to methods of treating prostate cancer, methods of
imaging, or methods related to fertility, contraceptive, andropause and muscle
or bone mass uses.

      1.13 "Major Markets" shall mean and include the United States, Great
Britain, France, Germany, and Japan.

      1.14 "Residual Alliance" shall mean any Alliance that is not a Joint
Alliance.

                                       3.
<PAGE>

      1.15 "Residual Alliance Party" or "Residual Alliance Parties" shall mean
GTx, and any other party who is a member of a Residual Alliance, including
Sub-sublicensees.

      1.16 "Residual Alliance Revenue" shall mean all cash, Sublicense or
Sub-sublicense fees, and running royalties and all other consideration paid to
GTx by a Residual Alliance or a Residual Alliance Party in consideration for the
granting of rights to the Licensed Patents and/or Licensed Technology.

      1.17 "Sublicense(s)" shall mean any sublicense granted by GTx, to a Joint
Alliance, Joint Alliance Party, Residual Alliance or a Residual Alliance Party.

      1.18 "Sublicensee(s)" shall mean any Joint Alliance, Joint Alliance Party,
Residual Alliance or Residual Alliance Party, to whom GTx has granted
sublicenses pursuant to this Agreement.

      1.19 "Sub-sublicense(s)" shall mean any sub-sublicense granted by a Joint
Alliance, Joint Alliance Party, Residual Alliance or a Residual Alliance Party,
other than GTx , to a Third Party or to an Affiliate of a Joint Alliance Party
or Residual Alliance Party other than GTx.

      1.20 "Sub-sublicensee(s)" shall mean any party to whom a Joint Alliance,
Joint Alliance Party, Residual Alliance or a Residual Alliance Party, other than
GTx, has granted Sub-sublicenses to pursuant to this Agreement.

      1.21 "Third Party" or "Third Parties" shall mean any non-affiliated party
or parties other than GTx, a Joint Alliance, a Joint Alliance Party, a Residual
Alliance, a Residual Alliance Party, UTRC or The University of Tennessee.

      1.22 "Valid Claim" shall mean (a) a claim of an issued patent which has
not expired and which has not been held revoked, invalid or unenforceable by
decision of a court or other governmental agency of competent jurisdiction,
unappealable or unappealed with the time allowed for appeal having expired, and
which has not been admitted to be invalid through reissue or disclaimer or
otherwise; or (b) any claim of a pending patent application, which i) was filed
in good faith; and ii) has not been pending for more than eight (8) years.

                                   SECTION 2

                                      Grant

      2.1 UTRC hereby grants to GTx an exclusive, worldwide right and license,
with the right to grant Sublicenses and to permit Sub-sublicenses to practice
under and use the Licensed Patents and the Licensed Technology to make, have
made, use, market, sell, have sold, import, distribute, and offer for sale any
Licensed Product, Licensed Process or Generic Product. UTRC hereby agrees,
subject to the terms and conditions herein contained, that the term "exclusive"
means that UTRC shall not grant any other license to any third party or take any
action inconsistent with the rights granted to GTx under this Agreement relating
to the Licensed Patents or Licensed Technology.

                                       4.
<PAGE>

      2.2 GTx agrees that the Contributors and The University of Tennessee shall
have the royalty-free right to practice under the Licensed Patents and to
utilize the Licensed Technology for non-commercial educational, research, and
academic purposes only.

      2.3 GTx acknowledges that all or a portion of the Licensed Patents and
Licensed Technology was developed with the support of the United States
Government ("the Government"), and agrees that the Government retains rights in
the Licensed Patents and Licensed Technology as set forth in Title 35 U.S.C.
Section 200 et seq. All rights herein granted to GTx are subject to any such
rights held by the Government and further subject to any restrictions or
obligations that may be imposed by the Government pursuant to such riGhts.

      2.4 GTx shall have the right to enter into Sublicenses and to permit
Sub-sublicense agreements, as the case may be, with respect to the Licensed
Patents and Licensed Technology, subject to notifying UTRC of the identity and
address of each Sublicensee or Sub-sublicensee within thirty (30) days after
execution of such agreement by the parties thereto. No GTx Affiliate, Joint
Alliance, Joint Alliance Party, Residual Alliance, Residual Alliance Party, or
their Affiliates, shall have the right to practice under the Licensed Patents or
utilize the Licensed Technology to make, have made, use, market, sell, have
sold, import, distribute, or offer for sale any Licensed Product, Licensed
Process or Generic Product in the absence of a written Sublicense or
Sub-sublicense. Any grant of rights by GTx, a Joint Alliance, a Joint Alliance
Party, a Residual Alliance, a Residual Alliance Party, or their Affiliates, to
practice under the Licensed Patents or to utilize the Licensed Technology to
make, have made, use, market, sell, have sold, import, distribute, or offer for
sale any Licensed Product, Licensed Process or Generic Product shall constitute
a Sublicense or Sub-sublicense, as the case may be. All Sublicenses and
Sub-sublicenses granted by GTx hereunder shall be subject to this Agreement in
all respects and shall include provisions that such Sublicensee or
Sub-sublicensee is being granted a license under the Licensed Patents and
Licensed Technology as described herein.

      2.5 GTx shall be responsible for its Affiliates, Sublicensees and
Sub-sublicensees and shall not grant any rights that are inconsistent with the
rights granted to and obligations of GTx hereunder. Each such Sublicense and
Sub-sublicense agreement shall include a requirement that the Sublicensee or
Sub-sublicensees, as the case may be, use its best efforts to bring the subject
matter of the Sublicense or Sub-sublicense, as the case may be, into commercial
use. In addition, each such Sublicense and Sub-sublicense agreement shall
include a requirement that the Sublicensee or Sub-sublicensee, as the case may
be, assign, transfer and convey to UTRC all right, title and interest in and to
Licensed Patents. Upon termination of this Agreement, each Sublicensee's or
Sub-sublicensee's as the case may be, rights under any Sublicense agreement
shall also terminate. No Sublicense Or Sub-sublicense shall relieve GTx of any
of its obligations under this Agreement. GTx shall forward to UTRC a complete
copy of each Sublicense or Sub-sublicense agreement, as the case may be
(including, without limitation, all amendments and addenda), granted hereunder
within thirty (30) days after execution of such agreement by the parties
thereto, provided that UTRC shall receive such information and documents in
confidence and shall not publicly disclose, discuss or release such information
or document without the prior written approval of GTx except for the purposes of
enforcement of UTRC's rights. GTx shall be responsible for payment of royalties
from Joint Alliance Revenue and Residual Alliance Revenue provided, however,
that GTx may arrange for such payments to be made to UTRC by an Affiliate,
Sublicensee or Sub-sublicensee, with the understanding that UTRC's acceptance of

                                       5.
<PAGE>

such payments from an Affiliate, Sublicensee, or Sub-sublicensee does not
relieve GTx of the ultimate responsibility for any other or future payment
required hereunder. Each such Sublicense or Sub-sublicense agreement shall
include an audit right by UTRC of the same scope as provided in Article 5.1
herein with respect to GTx.

      2.6 Any act or omission of an Affiliate, Sublicensee or Sub-sublicensee
which would constitute a breach of this Agreement if performed by GTx shall be
deemed to be a breach by GTx of this Agreement, subject however to the same cure
provisions in favor of GTx or such Affiliate, Sublicensee or Sub-sublicensee, as
the case may be, as are otherwise provided herein for breach by GTx.

                                   SECTION 3

                                    Diligence

      3.1 GTx shall use its commercially reasonable best efforts to develop and
commercialize Licensed Products and Generic Products through a commercially
reasonable program for exploitation of the Licensed Patents and the Licensed
Technology.

                                   SECTION 4

                             Payments And Royalties

      4.1 For the rights, privileges and license granted hereunder, GTx shall
pay royalties to UTRC in the manner hereinafter provided until this Agreement
shall expire or be terminated. GTx shall pay to UTRC:

         A) License Issue Fee in the amount of [ * ], which UTRC acknowledges
has been fully paid by GTx.

         B) Annual License Maintenance Fees in the amount of [ * ], with the
first such License Maintenance Fee being due and payable on the [ * ] and each
succeeding License Maintenance Fee being due on the [ * ] of the Agreement;
provided, however, that running royalties payable in a given year shall be
creditable pro rata against the License Maintenance Fee already paid for that
year. License Maintenance Fees paid in excess of running royalties shall not be
creditable to running royalties for future years. The Annual License Maintenance
Fee shall be [ * ] at such time as GTx enters into a Joint Alliance, a Residual
Alliance or grants a Sublicense to a Third Party as described in Article 2.4.
[ * ] for the remainder of the Term of this Agreement, regardless of whether any
such Joint Alliance, Residual Alliance or Sublicense is terminated. This
increase shall not apply to a Sublicense granted to a GTx Affiliate that is 100%
owned by GTx.

         C) Reimbursement of Patent fees and expenses (including attorney fees)
incurred by UTRC, in the amount of [ * ] due within [ * ] from the Effective
Date of the Agreement, which UTRC acknowledges has been fully paid by GTx. In
addition, GTx will reimburse UTRC within [ * ] after receipt of an invoice for
any additional Patent fees and expenses incurred prior to assumption by GTx of
control of patent matters as provided in Article 6.1. As of the Effective Date
of this Amended and Restated Exclusive License Agreement, the

                                       6.
<PAGE>

amounts due for additional Patent fees and expenses that remain not invoiced by
UTRC total [ * ].

      4.2 In addition to the foregoing fees, GTx shall pay to UTRC the following
royalties for the term of this Agreement:

         A) [ * ] of Joint Alliance Revenue attributable to the use, sale or
distribution of License Products and Licensed Processes and a reduced percentage
of Joint Alliance Revenue attributable to the use, sale or distribution of
Generic Products, which reduced percentage shall be determined on a
country-by-country basis and in each country shall be calculated as the [ * ]
during the quarter divided by [ * ] during the same quarter [ * ] (provided that
in no event shall the reduced percentage [ * ]); and

         B) [ * ] of Residual Alliance Revenue attributable to the use, sale or
distribution of License Products and Licensed Processes and a reduced percentage
of Residual Alliance Revenue attributable to the use, sale or distribution of
Generic Products, which reduced percentage shall be determined on a
country-by-country basis and in each country shall be calculated as the [ * ]
during the quarter divided by [ * ] during the same quarter [ * ] (provided that
in no event shall the reduced percentage [ * ]).

      4.3 In the event that GTx, its Sublicensees or Sub-sublicensees
manufacture, make, use, sell import, or license a Licensed Product or perform a
Licensed Process using technologies for which royalties may be payable to UTRC
under this Article 4 and under one or more other UTRC/GTx license agreements,
GTx shall only be required to pay UTRC royalties under one such license
agreement, subject to the provisions of Article 5.2.

      4.4 Within [ * ] following the close of each calendar quarter in which
Joint Alliance Revenue is received by a Joint Alliance or Joint Alliance Party,
Residual Alliance Revenue is received by GTx, or amounts are received by a Joint
Alliance or Residual Alliance on account of the use, sale or distribution of a
Generic Product, as the case may be, payments shall be paid to UTRC or its
designee in United States dollars in Knoxville, Tennessee, or at such other
place as UTRC may reasonably designate consistent with the laws and regulations
controlling in any foreign country. In the event GTx arranges for any payment
under this Article 4.5 to be made to UTRC by an Affiliate, Sublicensee or
Sub-sublicensee pursuant to Article 2.5, if such payment is not received by UTRC
within the [ * ] period set forth herein, GTx shall be deemed to be in breach of
this Agreement, subject to the same cure provisions in favor of GTx as set forth
in Article 12. If any currency conversion shall be required in connection with
the payment of royalties hereunder, such conversion shall be made by using the
exchange rate prevailing at the Chase Manhattan Bank (N.A.) on the last business
day of the calendar quarterly reporting period to which such royalty payments
relate.

                                   SECTION 5

                               Reports And Records

      5.1 UTRC or its accounting agents shall have the right to inspect the
books of account of GTx. GTx shall keep full, true and accurate books of account
containing all particulars that

                                       7.
<PAGE>

may be necessary for the purpose of showing the amounts payable to UTRC
hereunder. Said books of account shall be kept at GTx's principal place of
business or the principal place of business of the appropriate division or
Affiliate of GTx to which this Agreement relates. Said books and the supporting
data shall be open at all reasonable times for [ * ] following the end of the
calendar year to which they pertain, to the inspection of UTRC or its accounting
agents for the purpose of verifying GTx's royalty statement. If any examination
reveals a shortage in amounts paid to UTRC equal to or greater than [ * ] of the
total amount due in the period under audit, GTx shall promptly reimburse UTRC
for the cost of the examination as well as the shortage, together with interest
thereon as provided in Article 5.4.

      5.2 GTx shall deliver to UTRC true and accurate reports to confirm a
royalty accounting hereunder within [ * ] after the close of each calendar
quarter in which Joint Alliance Revenue is received by a Joint Alliance or Joint
Alliance Party, or Residual Alliance Revenue is received by GTx, as the case may
be.

      These reports shall include at least the following, on a country-by-
country basis:

         (1) number of Licensed Products, Licensed Processes, or Generic
Products manufactured, used or sold by and/or for GTx and all Joint Alliance
Parties and Residual Alliance Parties;

         (2) total amounts received by GTx, a Joint Alliance or a Joint Alliance
Party for Licensed Products, Licensed Processes and Generic Products
manufactured, used or sold by and/or for GTx and any Joint Alliance, Joint
Alliance Party, Residual Alliance, or Residual Alliance Party.

         (3) accounting, for Joint Alliance Revenue or Residual Alliance
Revenue;

         (4) royalties due to UTRC pursuant to Sections 4.2 and 4.3 including
(i) the manner in which such royalties were calculated and (ii) in the event any
such royalties are payable to UTRC under this Agreement and under one or more
other UTRC/GTx license agreements, and notwithstanding that GTx is required to
pay such royalties under only one such license agreement, GTx shall set out in
its report the amount of such royalties covered by multiple license agreements
and identify all such license agreements to which such royalties apply;

         (5) names and addresses of all Joint Alliance Parties and Residual
Alliance Parties, including an identification of whether the party is a Joint
Alliance Party or a Residual Alliance Party;

         (6) dates that any Residual Alliance Revenue is received by GTx from a
Residual Alliance or any Residual Alliance Party and other information
pertaining to the determination of revenues due to UTRC; and

         (7) upon request by UTRC, any other information that may be necessary
for the purpose of showing the amounts payable to UTRC hereunder.

                                       8.
<PAGE>

      5.3 With each such report submitted, GTx shall pay to UTRC the royalties
due and payable under this Agreement. If no royalties shall be due, GTx shall so
report.

      5.4 Any amount owed by GTx under this Agreement that is not received by
UTRC on or before the date due shall bear interest at a per annum rate [ * ]
above the prime rate in effect at the Chase Manhattan Bank (N.A.) on the date
due. GTx shall also pay all reasonable collection costs at any time incurred by
UTRC in obtaining payment of amounts past due, including reasonable attorneys
fees. If the transfer or the conversion into United States Dollar equivalents in
any such instance is not lawful or possible, the payment of such part of the
royalties as is necessary shall be made by the deposit thereof, in the currency
of the country where the sales were made on which the royalty was based, to the
credit and account of UTRC or its nominee in any commercial bank or trust
company of its choice located in that country, prompt notice of which shall be
given by GTx to UTRC.

                                   SECTION 6

                               Patent Prosecution

      6.1 GTx shall assume complete control of the maintenance of the Licensed
Patents and will be responsible for preparing, filing, prosecuting and
maintaining all patent applications and patents, corresponding to or arising out
of the Licensed Technology. GTx shall use patent counsel of its own choice, at
its own expense. GTx agrees to pay all costs incident to the United States and
foreign applications, patents and like protection relating to the Licensed
Patents and the Licensed Technology, including all costs incurred for filing,
prosecution, issuance and maintenance fees as well as any costs incurred in
filing continuations, continuations-in-part, divisionals or related applications
and any re-examination or reissue proceedings. Subject to the provisions of
Article 6.4, GTx shall file and maintain patent applications corresponding to
the Licensed Technology in such countries as GTx in its sole discretion shall
select. UTRC shall have the sole and exclusive right, title and ownership in and
to all Licensed Patents corresponding to or arising out of the Licensed
Technology, which now exist or may exist in the future, including all United
States and foreign patent applications filed and patents issued pursuant to this
Article 6. GTx, its Sublicensees and Sub-sublicensees shall assign, transfer and
convey to UTRC all right, title and interest in and to all such Licensed
Patents. GTx shall be responsible for recording an assignment to UTRC of patent
applications filed pursuant to this Article 6 with the United States Patent and
Trademark Office and with each foreign Patent Office in which such applications
are filed. Upon request by GTx, UTRC will amend this Agreement as reasonably
necessary to confirm GTX's exclusive license in all such inventions conveyed to
UTRC as provided in this Section.

      6.2 GTx agrees to keep UTRC informed, at GTx's expense, of filing and
prosecutions pursuant to this Article 6 including submitting to UTRC copies of
all patent applications, official actions and responses thereto within thirty
(30) days of filing or receipt, as the case may be. GTx agrees that it will
reimburse UTRC for its reasonable attorneys fees that UTRC reasonably incurs for
review by outside counsel of the material received from GTx. GTx shall consult
with UTRC regarding any abandonment of the Licensed Patents or the prosecution
of patent applications described in Article 6.1 prior to such abandonment.

                                       9.
<PAGE>

      6.3 UTRC agrees to reasonably cooperate with GTx, at GTx's request and
expense, to whatever extent is reasonably necessary to procure patent protection
of any rights, including fully agreeing to execute any and all documents to
provide GTx the full benefit of the licenses granted herein with copies of
correspondence with Patent Offices concerning the Licensed Patents.

      6.4 In the event that GTx decides not to continue prosecution of any
United States or foreign patent application to issuance or maintain any United
States or foreign patent on technology described or claimed in the Licensed
Patents or the Licensed Technology in a certain jurisdiction, GTx shall timely
notify UTRC in writing in order that UTRC may continue said prosecution or
maintenance of such patent applications or patents at its option and at its own
expense in such jurisdiction. GTx's right under this Agreement to practice the
invention(s) under such patents and patent applications shall immediately
terminate in such jurisdiction upon UTRC's assuming said costs provided that the
application, in which GTx decides not to continue prosecution or the patent
which GTx decides not to maintain, is before the Patent Offices of a country
included in Major Markets. GTx shall not be considered in default and this
Agreement shall not terminates to any particular jurisdiction, if GTx decides
not to continue prosecution of a patent application to issuance or maintain any
patent in any other country besides those included in Major Markets. If GTx
fails to notify UTRC in sufficient time for UTRC to continue prosecution, or the
maintenance of, a patent or patent application in a Major Market, GTx shall be
considered in default of this Agreement.

      6.5 GTx and all its Sublicensees and Sub-sublicensees shall mark all
products covered by Licensed Patents with patent numbers in accordance with the
statutory requirements in the country (ies) of manufacture, use, and sale.

      6.6 At such time as it is reasonable to do so, but in any event prior to
any statutory bar date for filing a patent application of which GTx has been
made aware, GTx shall prepare and submit a patent application directed toward
[*], entitled [*].

                                   SECTION 7

                                  Infringement

      7.1 GTx shall inform UTRC and UTRC shall inform GTx, promptly in writing
of any alleged assertion and/or claim of infringement of the Licensed Patents by
a Third Party and of any available evidence thereof.

      7.2 GTx shall have the right, but shall not be obligated, to prosecute at
its own expense all infringements of the Licensed Patents and, in furtherance of
such right, UTRC hereby agrees that GTx may include UTRC as a party plaintiff in
any such suit, without expense to UTRC. The total cost of any such infringement
action commenced or defended by GTx shall be borne by GTx. After deduction of
outstanding expenses, including attorneys fees of GTx, the balance remaining
from any such recovery shall be divided equally between GTx and UTRC until UTRC
shall have recovered in full any royalty payments to which it would have been
otherwise entitled to receive hereunder, but for such infringement, and any
remaining balance, if

                                      10.
<PAGE>

any, shall be retained by GTx. No settlement, consent, judgment or other
voluntary dismissal of such suits may be entered into without the consent of
UTRC, provided that such consent shall not be unreasonably withheld and that
UTRC shall not condition such consent on an increase in payments to UTRC
hereunder.

      7.3 If within six (6) months after having been notified of an alleged
infringement, GTx has not brought or is not diligently prosecuting an
infringement action, or if GTx has notified UTRC at any time prior thereto of
its intention not to bring suit against any alleged infringement of the Patents,
then, and in those events only, UTRC shall have the right, but shall not be
obligated, to prosecute at its own expense any infringement of the Licensed
Patents, and UTRC may, for such purposes, use the name of GTx as party
plaintiff. No settlement, consent judgment or other voluntary final disposition
of the suit may be entered into without the consent of GTx, which consent shall
not unreasonably be withheld. After deduction of outstanding expenses of UTRC,
including attorney fees and any expenses of GTx, including attorney fees
incurred prior to UTRC's pursuit of such infringement, the balance remaining
from any such recovery shall be divided equally between GTx and UTRC.

      7.4 In the event that GTx undertakes the enforcement and/or defense of the
Licensed Patents by litigation or an inter partes proceeding in the United
States or a foreign country against a Third Party, GTx may withhold up to [ * ]
of the payments otherwise thereafter due UTRC under Article 4 that are
attributable to sales in the country where such litigation or inter partes
proceeding takes place and apply the same toward reimbursement of up to half of
GTx's expenses, including reasonable attorneys' fees, in connection therewith.
GTx may not withhold any portion of the payments due UTRC under Article 4 in the
event that GTx undertakes the enforcement and/or defense of the Licensed Patents
by litigation or an inter partes proceeding in the United States or a foreign
country against an Affiliate, a Joint Alliance Party or a Residual Alliance
Party. Any recovery of damages by GTx for each such suit shall be applied first
in satisfaction of any unreimbursed expenses and legal fees of GTx relating to
such suit, and next toward reimbursement of UTRC for any payments under Article
4 past due or withheld and applied pursuant to this Article 7.

      7.5 In the event that a declaratory judgment action alleging invalidity or
noninfringement of any of the Licensed Patents shall be brought against UTRC,
GTx at its option shall have the right, within thirty (30) days after
commencement of such action, to intervene and take over the sole defense of the
action at its own expense.

                                   SECTION 8

                          Liability And Indemnification

      8.1 GTx shall at all times during the term of this Agreement, indemnify,
defend and hold UTRC, The University of Tennessee, and their respective
trustees, directors, officers, employees and Affiliates, harmless against all
claims, proceedings, demands and liabilities of any kind whatsoever, including
legal expenses and reasonable attorneys fees (collectively, the "Claims"),
arising out of the death of or injury to any person or persons or out of any
damage to property, resulting from the production, manufacture, sale, use,
lease, or consumption of the Licensed Products, Licensed Processes or Licensed
Technology or arising from any obligation or

                                      11.
<PAGE>

act of GTx hereunder, except for Claims arising from the willful misconduct or
misrepresentation by UTRC, The University of Tennessee, and their respective
trustees, directors, officers, employees and Affiliates. Infringement by a Joint
Alliance Party, a Residual Alliance Party, Sublicensees or Sub-sublicensees of a
Third Party patent shall not be deemed for purposes of this Agreement as an
improper action, omission, or negligent act on the part of UTRC, The University
of Tennessee or their respective trustees, directors, officers, employees or
Affiliates.

      8.2 GTx shall obtain and carry in full force and effect from the first
manufacture, use or sale of the Licensed Products, Licensed Processes or
Licensed Technology to [ * ] such manufacturing, use or sales cease, commercial,
general liability insurance which shall protect GTx and UTRC with respect to
events covered by Paragraph 8.1 above. Such insurance shall be written by a
reputable insurance company, shall list UTRC as an additional named insured
thereunder, shall be endorsed to include product liability coverage and shall
require thirty (30) days written notice to be given to UTRC prior to any
cancellation or material change thereof. The limits of such insurance shall not
be less than [ * ] per occurrence with an aggregate of [ * ] for personal injury
or death. GTx shall provide UTRC with Certificates of Insurance evidencing the
same.

      8.3 UTRC, ITS TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES, AND AFFILIATES
MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESSED
OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS
FOR A PARTICULAR PURPOSE, OR THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR
NOT DISCOVERABLE, IN ANY LICENSED PRODUCT, LICENSED PROCESS, LICENSED TECHNOLOGY
OR GENERIC PRODUCT. IN NO EVENT SHALL UTRC, THE UNIVERSITY OF TENNESSEE, OR
THEIR RESPECTIVE TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES OR AFFILIATES BE
LIABLE FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING, WITHOUT
LIMITATION, ECONOMIC DAMAGE, INJURY TO PROPERTY OR LOST PROFITS, REGARDLESS OF
WHETHER UTRC OR THE UNIVERSITY SHALL BE ADVISED, SHALL HAVE OTHER REASON TO
KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY OF ANY OF THE FOREGOING, EXCEPT
FOR NEGLIGENCE, FRAUD, OR MISREPRESENTATION BY UTRC, ITS TRUSTEES, DIRECTORS,
OFFICERS, EMPLOYEES, AND AFFILIATES. NOTHING IN THIS AGREEMENT SHALL BE
CONSTRUED AS:

         A. A REPRESENTATION MADE OR WARRANTY GIVEN BY UTRC THAT THE PRACTICE BY
GTx OF THE LICENSE GRANTED HEREUNDER SHALL NOT INFRINGE THE PATENTS OF ANY THIRD
PARTY;

         B. A REPRESENTATION MADE OR WARRANTY GIVEN BY UTRC THAT ANY PATENT
APPLICATION INCLUDED IN THE PATENTS WILL ULTIMATELY ISSUE AS A PATENT;

         C. A REPRESENTATION MADE OR WARRANTY GIVEN THAT GTx SHALL HAVE THE
RIGHT TO USE ANY PORTION OF THE LICENSED PATENTS THAT IS CLAIMED IN A PATENT OF
ANY THIRD PARTY;

                                      12.
<PAGE>

         D. A REQUIREMENT THAT UTRC SHALL BE RESPONSIBLE FOR THE EXPENSES OF
FILING OR PROSECUTING ANY PATENT APPLICATION OR MAINTAINING ANY LICENSED PATENTS
IN FORCE;

         E. AN OBLIGATION ON THE PART OF UTRC TO BRING OR PROSECUTE ACTIONS OR
SUITS AGAINST THIRD PARTIES FOR INFRINGEMENT OF THE LICENSED PATENTS OR FOR
UNAUTHORIZED USE OF THE PATENTS OR MISAPPROPRIATION OF THE LICENSED TECHNOLOGY;

         F. AN OBLIGATION ON THE PART OF UTRC TO DEFEND ANY ACTION OR SUIT
BROUGHT BY ANY THIRD PARTY;

         G. A REPRESENTATION MADE OR WARRANTY GIVEN BY UTRC AS TO THE SAFETY,
RELIABILITY OR EFFICACY OF: 1) THE LICENSED TECHNOLOGY OR THE INVENTIONS COVERED
BY THE LICENSED PATENTS; OR 2) ANY LICENSED PRODUCT OR LICENSED PROCESS THAT
INCORPORATES THE LICENSED PATENTS OR UTILIZES THE LICENSED PATENTS IN ITS
PRODUCTION, MANUFACTURE OR PERFORMANCE OR ANY GENERIC PRODUCT THAT INCORPORATES
THE LICENSED TECHNOLOGY OR UTILIZES THE LICENSED TECHNOLOGY IN ITS PRODUCTION,
MANUFACTURE OR PERFORMANCE; and

         H. A REPRESENTATION MADE OR WARRANTY GIVEN BY UTRC THAT ANY OF THE
CONTRIBUTORS WILL AGREE TO PROVIDE TECHNICAL ASSISTANCE OR CONSULTATION TO GTx,
OR THAT SUCH TECHNICAL ASSISTANCE OR CONSULTATION, IF PROVIDED, WOULD BE
SUFFICIENT TO ENABLE GTx TO SUCCESSFULLY EXPLOIT THE LICENSED TECHNOLOGY OR THE
LICENSED PATENTS.

      8.4 UTRC represents and warrants that to the best of its actual knowledge:
(i) the Licensed Patents are valid and enforceable; (ii) it has the full power
to enter into this Agreement, to carry out its obligations under this Agreement,
and to grant the rights granted to GTx herein; (iii) it has not previously
granted and shall not grant to any Third Party any rights which are inconsistent
with the rights granted to GTx herein, (iv) it is the sole owner of the entire
right, title, and interest in and to the Licensed Patents and Licensed
Technology; and (v) it has fully complied with all requirements of 35 U.S.C.
Section 200 et seq. and all implementing regulations necessary to perfect title
to the rights and license granted to GTx herein.

      8.5 UTRC acknowledges and understands that Dr. Mitchell S. Steiner is an
employee of The University of Tennessee and that he was and is currently the
Chief Executive Officer of GTx.

      8.6 GTx represents that: 1) it has full corporate power and authority to
enter into this Agreement and carry out all the provisions of this Agreement; 2)
it is authorized to execute this Agreement on its behalf; 3) the person
executing this Agreement is duly authorized to do so; and 4) no consent,
approval or authorization of any other party is required.

                                      13.
<PAGE>
                                   SECTION 9

                                 Export Controls

      9.1   GTx acknowledges that it is subject to United States laws and
regulations controlling the export of technical data, computer software,
laboratory prototypes and other commodities (including the Arms Export Control
Act, as amended, and the United States Department of Commerce Export
Administration Regulations). The transfer of such items may require a license
from the cognizant agency of the United States Government and/or written
assurances by GTx that GTx shall not export data or commodities to certain
foreign countries without prior approval of such agency. UTRC neither represents
that a license shall not be required nor that, if required, it shall be issued.

                                   SECTION 10

                                Non-Use Of Names

      10.1  GTx shall not use the names or trademarks of UTRC or the University
of Tennessee, nor any adaptation thereof, in any advertising, promotional or
sales literature without prior written consent obtained from UTRC, except that
GTx may state that it has licensed the Licensed Patents and Licensed Technology
from UTRC.

      10.2  UTRC shall not use the names or trademarks of GTx, nor any
adaptation thereof in any advertising, promotional or sales literature without
prior written consent obtained from GTx except that UTRC may state that it has
licensed the Licensed Patents and Licensed Technology to GTx.

                                   SECTION 11

                               Dispute Resolution

      11.1  Except for the right of either party to apply to a court of
competent jurisdiction for a temporary restraining order, a preliminary
injunction, or other equitable relief to preserve the status quo or to prevent
irreparable harm, any and all claims, disputes or controversies arising under,
out of, or in connection with this Agreement, shall be resolved upon thirty (30)
days written notice of either party to the other by final and binding
arbitration in Knoxville, Tennessee under the Commercial Arbitration Rules of
the American Arbitration Association, or the Patent Arbitration Rules if
applicable, then in effect. The arbitrator(s) shall have no power to add to,
subtract from or modify any of the terms or conditions of this Agreement, nor to
award punitive damages. The prevailing party in any such arbitration shall, in
addition to recovering reasonable out-of-pocket costs of the arbitration, be
entitled to an award of reasonable attorneys fees incurred in connection with
the arbitration, with any action necessary to perfect the arbitration award as a
judgment, and for any collection action required to secure payment of any
arbitration award. Any award rendered in such arbitration may be entered and
enforced by either party in either the courts of the State of Tennessee or in
the United States District Court for the Eastern District of Tennessee, to whose
jurisdiction for such purposes UTRC and GTx each hereby irrevocably consents and
submits, or in any other United States court having jurisdiction.

                                      14.
<PAGE>
      11.2  Notwithstanding the foregoing, nothing in this Article shall be
construed to waive any rights or timely performance of any obligations existing
under this Agreement.

                                   SECTION 12

                        Term Of Agreement And Termination

      12.1  Unless earlier terminated, as hereinafter provided, the Term of this
Agreement shall be for the longer of twenty (20) years or the last to expire
term of any patent or patent application having a Valid Claim covering the
Licensed Patents. After such expiration, GTx shall have a perpetual,
royalty-free license to the Licensed Patents and Licensed Technology.

      12.2  In the event of default or failure by GTx to perform any of the
terms, covenants or provisions of this Agreement, GTx shall have thirty (30)
days after the giving of written notice of such default by UTRC to correct such
default. If such default is not corrected within the said thirty (30) day
period, UTRC shall have the right, at its option, to cancel and terminate this
Agreement. The failure of UTRC to exercise such right of termination for
non-payment of royalties or otherwise shall not be deemed to be a waiver of any
right UTRC might have, nor shall such failure preclude UTRC from exercising or
enforcing said right upon any subsequent failure by GTx.

      12.3  UTRC shall have the right, at its option, to cancel and terminate
this Agreement in the event that GTx shall become involved in insolvency,
dissolution, bankruptcy or receivership proceedings affecting the operation of
its business. In the event of termination of this Agreement pursuant to Articles
12.2 or 12.3 hereof, all rights to the Licensed Patents shall revert to UTRC.

      12.4  Upon termination of this Agreement for any reason, nothing herein
shall be construed to release either party from any obligation that matured
prior to the effective date of such termination; and Articles 1, 5, 8, 9-12, 18,
20, and 21 shall survive any such termination.

      12.5  No termination of this Agreement shall constitute a termination or a
waiver of any rights of either Party against the other Party accruing at or
prior to the time of such termination. The obligations of Articles 5 and 13
shall survive termination of this Agreement.

      12.6  GTx shall have the right to terminate this Agreement at any time on
three (3) months notice to UTRC, and upon payment of all amounts due UTRC
through the effective date of the termination.

                                   SECTION 13

                                  Assignability

      13.1  This Agreement shall be binding upon and shall inure to the benefit
of UTRC and its assigns and successors in interest, and shall be binding upon
and shall inure to the benefit of GTx and its assigns and successors to all or
substantially all of its assets or business to which this Agreement relates, but
shall not otherwise be assignable or assigned by GTx without prior written
approval by UTRC being first obtained, which approval shall not be unreasonably
withheld; provided that, for purposes hereof, GTx shall have the right to assign
this Agreement

                                      15.
<PAGE>
to an Affiliate of GTx (or any entity into which GTx shall have been merged or
consolidated, provided that at least 51% of such merged or consolidated entity
is owed by shareholders holding at least 51% of GTx immediately prior to such
merger or consolidation) without obtaining the prior written approval of UTRC.
No assignment shall be deemed effective unless such assignee has agreed in
writing to be bound by the terms and provisions of this Agreement. Any attempt
to assign or assignment made in violation of this Article 13.1, shall be void ab
initio.

                                   SECTION 14

                             Governmental Compliance

      14.1  GTx shall at all times during the term of this Agreement and for so
long as it shall make, use or sell Licensed Products, Licensed Processes or
Licensed Technology comply and cause its sublicensees to comply with all laws
that may control the import, export, manufacture, use, sale, marketing,
distribution and other commercial exploitation of Licensed Products, Licensed
Processes or Licensed Technology or any other activity undertaken pursuant to
this Agreement.

                                   SECTION 15

                                     Notices

      15.1  Any notice or other communication under this Agreement shall be in
writing and shall be deemed to have been given: when delivered personally
against receipt therefor; one day after being sent by Federal Express or similar
overnight delivery; or three days after being mailed registered or certified
mail, postage prepaid, to a party hereto at the address set forth below, or to
such address as such party shall give by notice hereunder to the other party to
this Agreement.

            If to UTRC:       The University of Tennessee Research Corporation
                              1534 White Avenue, Suite 403
                              Knoxville, Tennessee, U.S.A. 37996-1527
                              Attn:    President

            If to GTx:        3 N. Dunlap Street, 3rd Floor
                              Memphis, Tennessee 38163
                              Attn:    Dr. Mitchell Steiner
                              Title:   Chief Executive Officer

            with a copy to:   Henry P. Doggrell, General Counsel, GTx, Inc.

                                   SECTION 16

                           Severability Of Provisions

      16.1  If any provision of this Agreement shall be declared by a court of
competent jurisdiction to be invalid, illegal or incapable of being enforced in
whole or in part, the remaining conditions and provisions or portions thereof
shall nevertheless remain in full force and effect

                                      16.
<PAGE>
and enforceable to the extent they are valid, legal and enforceable, and no
provision shall be deemed dependent upon any other covenant or provision unless
so expressed herein.

                                   SECTION 17

                                  Governing Law

      17.1  This Agreement shall be deemed to be subject to, and have been made
under, and shall be construed and interpreted in accordance with the laws of the
State of Tennessee. This Agreement is expressly acknowledged to be subject to
all federal laws including but not limited to the Export Administration Act of
the United States of America. No conflict-of-laws rule or law that might refer
such construction and interpretation to the laws of another state, republic, or
country shall be considered. The Parties irrevocably and unconditionally agree
that the exclusive place of jurisdiction for any action, suit or proceeding for
a temporary restraining order, a preliminary injunction, or other equitable
relief to preserve the status quo or to prevent irreparable harm, arising under,
out of, or in connection with this Agreement ("Actions"), shall be in the courts
of the United States of America sitting in the city, state and country of State
of Tennessee, or, if such courts shall not have jurisdiction over the subject
matter thereof, in the courts of the State of Tennessee sitting therein, and
each such party hereby irrevocably and unconditionally agrees to submit to the
jurisdiction of such courts for the purposes of any such Actions. If any such
State court also does not have jurisdiction over the subject matter thereof,
then such an Action may be brought in the federal or state courts located in the
states of the principal place of business of any Party hereto.

                                   SECTION 18

                                 Confidentiality

      18.1  Nothing herein shall preclude a Party from disclosing the existence
of this Agreement and the general scope of the license granted hereunder.
However, neither Party shall disclose the economic terms of this Agreement.

      18.2  Subject to the exceptions set forth herein, all information or
material disclosed pursuant to this Agreement and/or related to the Licensed
Patents, Licensed Products, Licensed Process, Licensed Technology and Generic
Products shall be confidential ("Confidential Information"). Recipient of the
Confidential Information ("Receiving Party") agrees to hold in confidence, and
not to distribute or disseminate to any Person or entity, for any reason for a
period of five (5) years after receipt, any Confidential Information received,
under or relating to this Agreement, except for Confidential Information which:

            (I)   was known or used by the Receiving Party prior to the date of
disclosure to the Receiving Party as evidenced by written records; or

            (II)  either before or after the date of disclosure is lawfully
disclosed to the Receiving Party by sources other than the Providing Party which
are rightfully in possession of the Confidential Information and not subject to
any obligation of confidentiality, as evidenced by written records; or

                                      17.
<PAGE>
            (III) either before or after the date of disclosure to the Receiving
Party becomes published, through no fault or omission on the part of the
Receiving Party; or

            (IV)  is independently developed by or for the Receiving Party
without reference to, knowledge of, or reliance upon the Confidential
Information as evidenced by written records;

            (V)   is required to be disclosed by the Receiving Party to comply
with applicable laws, to defend or prosecute litigation or to comply with
governmental regulations, provided that the Receiving Party provides prior
written notice of such disclosure to the Providing Party and takes reasonable
and lawful actions to avoid and/or minimize the degree of such disclosure,
provided that specific information shall not be deemed to be within any of these
exclusions merely because it is embraced by more general information falling
with these exclusions; or

            (VI)  is developed by or for the Receiving Party without reference
to, knowledge of, or reliance upon any of the Confidential Information.

      18.3  The Parties recognize that GTx has entered into certain research
agreement(s) with The Ohio State University Research Foundation, The University
of Tennessee has entered into certain subcontract agreement(s) with The Ohio
State University Research Foundation and that GTx has entered into certain
consulting agreement(s) with one or more of the Contributors, which agreements
may contain confidentiality obligations and/or restrictions on publication
regarding, information or material related to this Agreement, the Licensed
Patents and/or the Licensed Technology. While UTRC acknowledges the need for
such confidentiality obligations and restrictions on publication in order for
GTx to preserve United States and foreign patent rights, UTRC makes no
representations or warranties, and has no obligation hereunder, regarding the
confidentiality or publication obligations of The University of Tennessee, the
Contributors or The Ohio State University Research Foundation.

      18.4  The Parties agree that counsel of the Parties, who have a duty of
confidentiality to the respective Parties, may receive Confidential Information.

                                   SECTION 19

                                   Reformation

      19.1  All Parties hereby agree that neither Party intends to violate any
public policy, statutory or common law, rule, regulation, treaty or decision of
any government agency or executive body thereof of any country or community or
association of countries; that if any word, sentence, paragraph or clause or
combination thereof of this Agreement is found, by a court or executive body
with judicial powers having jurisdiction over this Agreement or any of its
Parties hereto, in a final unappealed order to be in violation of any such
provision in any country or community or association of countries, such words,
sentences, paragraphs or clauses or combination shall be inoperative in such
country or community or association of countries, and the remainder of this
Agreement shall remain binding upon the Parties hereto.

                                      18.
<PAGE>
                                   SECTION 20

                                   Non-Waiver

      20.1  The Parties covenant and agree that if a Party fails or neglects for
any reason to take advantage of any of the terms provided for the termination of
this Agreement or if a Party, having the right to declare this Agreement
terminated, shall fail to do so, any such failure or neglect by such Party shall
not be a waiver or be deemed or be construed to be a waiver of any cause for the
termination of this Agreement subsequently arising, or as a waiver of any of the
terms, covenants or conditions of this Agreement or of the performance thereof.
None of the terms, covenants and conditions of this Agreement may be waived by a
Party except by its written consent.

                                   SECTION 21

                                Entire Agreement

      21.1  This Agreement, as amended and restated herein, contains the entire
agreement and understanding of the parties as of the Effective Date with respect
to the subject matter hereof, supersedes any prior agreements and understandings
with respect thereto and cannot be modified, amended or waived, in whole or in
part, except in writing signed by the Party to be charged. Any such purported
non-written modification, amendment, or waiver shall be null and void. A
discharge of the terms of this Agreement shall not be deemed valid unless by
full performance of the Parties hereto or by writing signed by the Parties
hereto. A waiver by UTRC of any breach by GTx of any provision or condition of
this Agreement to be performed by GTx shall not be deemed a waiver of similar or
dissimilar provisions or conditions at the same or any prior or subsequent time.

                                      19.
<PAGE>
      In Witness Whereof, the Parties hereto have executed and delivered this
Agreement in multiple originals by their duly authorized officers and
representatives on the respective dates shown below, but effective as of the
Agreement Date. The undersigned representative of UTRC is authorized to execute
this Agreement on its behalf and bind UTRC to the terms and conditions set
forth.

The University Of Tennessee Research       Gtx, Inc. ("GTx")
Corporation ("UTRC")

By: /s/ Ann J. Roberson                    By: /s/ Mitchell S. Steiner
    --------------------------------           ---------------------------------
Name:    Ann J. Roberson                   Name:    Mitchell S. Steiner
Title:   President                         Title:   Chairman and Chief Executive
                                                    Officer

Date:  6-3-02                              Date: 6/3/02
       -----------------------------             -------------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                      20.
<PAGE>
                                   SCHEDULE 1

<TABLE>
<CAPTION>
     EPLC FILE NO.       TITLE       INVENTOR(S)/APPLICANT    SERIAL NOD PA NO.      FILING DATE       STATUS
<S>                      <C>         <C>                      <C>                    <C>               <C>
     [ * ]               [ * ]       [ * ]                    [ * ]                  [ * ]             [ * ]
</TABLE>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       1.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00057-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00057-of-00352.parquet"}]]